Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan
| العنوان: | Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan |
|---|---|
| المؤلفون: | Satoshi Takahashi, Nobuyuki Hamajima, Yoshiko Atsuta, Hisashi Sakamaki, Mitsune Tanimoto, Akira Hiraoka, Masamitsu Yanada, Noriyuki Hirabayashi, Yoshinobu Kanda, Nobuhiko Emi, Ryuji Tanosaki, Shingo Kato, K Iwato, Shinichiro Okamoto, Tomoki Naoe |
| المصدر: | Bone Marrow Transplantation. 34:331-337 |
| بيانات النشر: | Springer Science and Business Media LLC, 2004. |
| سنة النشر: | 2004 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Time Factors, Adolescent, medicine.medical_treatment, Graft vs Host Disease, chemical and pharmacologic phenomena, Hematopoietic stem cell transplantation, Tacrolimus, Japan, immune system diseases, Internal medicine, Humans, Medicine, Aged, Transplantation, business.industry, Histocompatibility Testing, Siblings, Hazard ratio, Retrospective cohort study, Hematology, Middle Aged, Ciclosporin, medicine.disease, Tissue Donors, Histocompatibility, Surgery, Regimen, Treatment Outcome, surgical procedures, operative, Graft-versus-host disease, Acute Disease, Chronic Disease, Cyclosporine, Female, business, Immunosuppressive Agents, Follow-Up Studies, Stem Cell Transplantation, medicine.drug |
| الوصف: | Despite recent advances, graft-versus-host disease (GVHD) remains the main cause of treatment failure for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Tacrolimus (FK506) has been increasingly used in place of cyclosporine (CSP), and several studies have shown that FK506 reduces the incidence of acute GVHD more effectively than does CSP. However, no survival benefits have been demonstrated, and no established consensus exists on the choice of these immunosuppressive agents. To compare a CSP-based and an FK506-based regimen, we performed a large-scale retrospective study by using the data of 1935 patients who underwent HSCT from HLA-identical sibling donors (SIB-HSCT) and 777 patients who underwent HSCT from unrelated donors (UD-HSCT). For patients undergoing UD-HSCT, FK506 significantly reduced the risk of acute GVHD and treatment-related mortality (TRM) without an increase in relapse, thus improving overall survival (OS) (hazard ratio (HR): 2.20, 95% confidence interval (CI): 1.60-3.04, P |
| تدمد: | 1476-5365 0268-3369 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772368a074283fbd94ee3c8c758ea58e https://doi.org/10.1038/sj.bmt.1704596 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....772368a074283fbd94ee3c8c758ea58e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765365 02683369 |
|---|